Belgium’s long-standing advantage in early phase approvals
Belgian law has historically allowed accelerated approval timelines for early phase, mononational trials. In practice, phase I studies have moved from submission to approval significantly faster than the timelines defined under the European Clinical Trial Regulation. Validation and assessment are handled within compressed windows when dossiers are complete and responses to questions are timely. Over many years of regulatory submissions, this has consistently resulted in approvals well below the CTR maximum of 106 days, creating a track record of speed combined with predictability.
This established regulatory environment has positioned Belgium as a preferred location for early translational research, where rapid progression from protocol submission to study start is critical.
For a deeper dive into Belgium’s regulatory timelines, read the Clinical Trials Regulation (CTR) whitepaper or watch our CTR webinar recording.
What changed for CHIM studies in January 2026
As of January 2026, Belgian authorities have formally extended accelerated timelines to phase I/II and phase II mononational trials, explicitly including Controlled Human Infection Models (CHIM) studies.
For CHIM trials submitted in Belgium today, the maximum approval timeline is 59 days from submission, including the assessment of requests for information. Even when questions arise, reviews are conducted within shortened cycles, preserving the overall timeline. For monoclonal antibody studies, where the CTR allows for substantial extensions, Belgium applies only a limited additional review window, keeping total approval timelines far below the European maximum.
CHIM studies are designed to deliver early efficacy data that supports go or no-go decisions. At this stage of development, speed directly influences investor confidence, development strategy and resource allocation.
An ecosystem built to support fast decisions
Regulatory speed only delivers value when the surrounding ecosystem can keep pace. In Belgium, several structural factors reinforce the timeline advantage and turn faster approvals into a real competitive edge.
Belgium has one of the highest concentrations of clinical trial sites in Europe, supported by a biotech sector that accounts for roughly 7% of national GDP.B iopharmaceuticals rank among the country’s top export products, making early phase research economically strategic. This context matters. Regulators, ethics committees and investigators routinely assess early phase trials, resulting in pragmatic, experience-driven reviews.
In Antwerp, CHIM units, GMP manufacturing for IMP, clinical pharmacology beds and high-grade labs sit within close proximity. For early phase programs with limited stability data or tight logistics, that integration removes operational delays.
Experience with challenge models further strengthens this CHIM hub. Mature influenza H3N2 challenge models and the newly validated RSV-A challenge model (RSV-NICA) operate within well-established ethical and safety frameworks, reducing start-up uncertainty and execution risk for sponsors.
What this means for early phase sponsors
With accelerated timelines now clearly and consistently applying to CHIM, Belgium offers a rare combination of scientific maturity, favorable regulatory approval timelines, regulatory familiarity and operational readiness. Sponsors can move from approval to execution without losing momentum, plan CHIM studies with confidence, reach first-subject-first-dose sooner and generate early efficacy data without unnecessary delay or regulatory uncertainty.
